1207947-49-6
C14H20N2O2
248.32
Ritlecitinib
JAK3
Availability: | |
---|---|
Supply Chain
As of September 14, 2024, there are 36 potential suppliers manufacturing Ritlecitinib intermediate benzyl (2S,5R)-5-amino-2-methylpiperidine-1-carboxylate (CAS No. 1207947-49-6), including 23 factories, among which:
- The 25th percentile has an average registered capital of 1 million CNY;
- The 50th percentile has an average registerd capital of 5.13 million CNY;
- The 75th percentile has an average registered capital of 10 million CNY.
Feeling overwhelmed? Contact Unibest if you need us to quality-check other sources to strengthen your supply chain or to find a tailored solution for your specific procurement request.
Usage and ROS Analysis
Three moieties can be identifed from Ritlecitinib structure:
Part A. The Adenine moiety, which is a common molecular building block for JAK inhibitor (read more about such magic bullet in drug development here)
Part B. The chiral moiety with two chiral centers; during API synthesis, the chiral purity of relevant intermediates is essential checkpoint for the cis conformation of Ritlecitinib API
Part C. The Acrylamide moiety
From the above Ritlecitinib synthesis map, an essential synthesis module is to form the Part B - cis chiral moiety, and the correct isomer can be conjugated with other two parts.
This Ritlecitinib intermediate, benzyl (2S,5R)-5-amino-2-methylpiperidine-1-carboxylate, CAS No. 1207947-49-6, contains two chrial centers. It has it hydrochloride salt form as CAS No. 1207853-23-3 that is an essential Ritlecitinib intermediate described in the Pfizer patents.